Speakers & Papers
Lucy Robertshaw has been running her own consultancy business for the past 4 years. Based near Stockholm, Sweden, the firm provides international business development services to organisations within the life science sector. Lucy started her career within the medical sector, later adding a HNC in Business Management and Administration. She has worked for AstraZeneca in the company’s Global Redeployment Project, assisting with site closures and laboratory equipment sales. Lucy has been working with Swedish and English clients such as APL, CR Competence, Liquidity Services and she is an active member of One Nucleus.
Sarah Haywood, Chief Executive Officer, MedCity
Sarah Haywood became Chief Executive Officer of MedCity in December 2015, after fulfilling the role in an acting capacity and then as COO since MedCity’s launch in April 2014.
Sarah is a graduate of the NHS Management Training Scheme in Wales and started her career in the NHS, working in a number of NHS Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as the Head of Operations for a neuroscience drug discovery unit, located on the UCL campus.
From there, Sarah joined the civil service and undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BEIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BEIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. In January 2014 she joined London & Partners where she worked with Dr Eliot Forster to establish MedCity.
Sarah has a degree in Biology from the University of Oxford, a post graduate diploma in management and an MA in human resources management; she is a chartered fellow of the Chartered Management Institute.
Dr Christelle Kerouedan
Dr Christelle Kerouedan – Associate Partner
Christelle has a 20 year career spanning research, communications, and business management and thus combines strong communications skills gained in the Life Sciences, Pharmaceuticals and Cleantech sectors, with hands-on entrepreneurial management skills and a deeply rooted science understanding. She manages significant client projects, and supports the Life Sciences team in operational management and marketing. She has an MSc in Immunology, Genetics and Molecular Biology, and PhD in Immunology from Imperial College. Born in France, she has lived in the UK for more than 20 years and is fluent in both French and English.
Anette Orheim, Communications Director, Medicon Village
With a degree in Social Science and Communication, Anette Orheim started out her carrier at Ifö Sanitär. She then continued to Skånetrafiken, as a public relations coordinator. At AstraZeneca, Anette Orheim held positions as a Public Relations manager at the Swedish MC and in Global Marketing. She then continued to Lund University, as a Communications Director and also in positions in External Affairs. Being a pioneer as part of a small team starting up Medicon Village, Medicon Village is now an established science park.
Medicon Valley Alliance
Petter Hartman, CEO, Medicon Valley Alliance
Petter is the CEO of Medicon Valley Alliance since June, 2015 and holds a Master of Political Science from University of Lund, Sweden. At Medicon Valley Alliance, Petter Hartman is involved in future strategies for the Medicon Valley region, general management within the public sector, project management, and pharmaceutical research & development. Petter comes from a post as Funding Manager at Medicon Valley Alliance. Prior to joining MVA Petter worked for the Secretariat for Interreg IV A Öresund-Kattegat-Skagerrak, Copenhagen as a project consultant with special responsibility for issues concerning cross-border relations and labor-market integration projects.
“My interest in society has always been in understanding concepts of social change and development. Whether it is about the impact of volunteering on a local level, or through the combination of multiple strategic efforts to create a better society in the long term; my goal is to work within a context where I can make a difference. The intention to work in cross-border relations has influenced my career in many ways and I expect it to do so in the future. I see a great challenge in working within an international context where different perspectives come together”.
Medicon Valley Alliance (MVA) is a Danish-Swedish cluster organization representing human life sciences in Medicon Valley. MVA is a non-profit member organization that carries out initiatives on behalf of the life science community in order to create new research and business opportunities, which strengthen the development of Medicon Valley. MVA’s member base comprises biotech, medtech and pharma companies of all sizes, CROs, CMOs, public organizations, universities, science parks, investors and business service providers.
Kerstin Jakobsson, executive vice president, Marketing and Business Development, Medicon Village
Kerstin has a MSc in bio- and analytical chemistry and she has over 25 years of industry experience in international business development from both large and small life science companies including as President of SpectraCure AB – a position she held from 2004 until 2010 – president of Ortoma AB and sales director of HemoCue AB. She has also served as international marketing manager for Foss A/S, Tecator AB and Perstorp Analytical AB. She is board member of Glycorex Transplantation AB and SmiLe incubator. Other former appointments are chairmen of Serstech AB, board member of Ideon AB, LYYN AB and Connect.
A new era for individualized treatments with Centre for Advanced Medical Products (CAMP) – Southern Sweden´s contribution to the National initiative
Region Skåne, Lund University and Medicon Village are collaborating in order to establish a center for development of innovative treatments at the frontiers of the cell- and gene therapy field. The trio will tie existing infrastructure with cutting edge academic, clinical and industrial competence. As part of the CAMP project, the cell and gene therapy centre will be placed at Medicon Village Science Park. Learn more about the process structure that will drive the technology from bench into clinics faster.
Tony Jones, One Nucelus
As CEO of One Nucleus the role encompasses the development of the strategic and operational strategy of the company. Leading our stakeholder and member engagement and evolution of our membership offer to reflect the current external environment and changing needs placed upon members’ businesses.
After completing a PhD in Biochemistry (1992) from the University of Southampton UK, Tony undertook several years of post-doctoral research in the oncology field, primarily with the Imperial Cancer Research Fund (now CRUK) In 1997, he moved into Technology Transfer with the Medical Research Council and later (1998) University College London, at the Wolfson Institute for Biomedical Research.
In November 2003, Tony took up the post of Director of Biotechnology & Healthcare at London First, managing the London Biotechnology Network and promotion of London’s excellence in healthcare research and delivery. In May 2010 he took London Biotechnology Network into the merger with ERBI, seeing this as the best manner in which to continue assisting member companies develop their businesses.
Peptonic Medical AB
Dr Johan Inborr, Peptonic Medical AB
Since October 2014, Dr Johan Inborr is the CEO of Peptonic Medical AB (Bromma, Sweden). Before assuming his current position, Johan was the Director of Business Development at Medivir AB responsible for in- and out-licensing of marketed or near-market products. He was also actively involved in Medivir’s M&A activities. Johan has held several commercial executive positions of Life Science companies in Sweden, UK and Germany, including CEO of AstaCarotene, VP Business Development of Carmeda and Innoventus and VP Marketing and Sales of Vironova and Finnsugar GmbH
Steno Diabetes Center Copenhagen
Allan Flyvbjerg, Steno Diabetes Center Copenhagen
Allan Flyvbjerg graduated from Aarhus University, Denmark in 1986, defended his thesis (DMSc) in 1993, became specialist in Endocrinology and Internal Medicine in 1999, Chief Physician in 2001, Professor in Experimental Medical Research in 2005, Chair in Endocrinology in 2009 and Dean of the Faculty of Health, Aarhus University in 2011.
In 2016 he was appointed CEO of Steno Diabetes Center Copenhagen (SDCC) and Professor in Clinical Endocrinology at the University of Copenhagen, Denmark.
His research embraces pre-clinical and clinical research focused on the pathogenesis leading to and treatment of diabetic angiopathy. He is author of approximately 600 scientific publications and is well-cited.
Allan Flyvbjerg was President of the Danish Diabetes Association (which has approximately 80,000 members) from 2000–2011 and is member of several national and international boards and councils. In the period 2016-2017 he was member of the ‘Growth team for life-science’ established by the Danish Government.
He was member of the editorial board of the Journal of the American Society of Nephrology from 2001–2004, and Associate Editor of Diabetologia from 2007–2013. He has received several national and international awards for his scientific contributions.
Staten Serum Intitut
Lasse Boding, Danish National Biobank, Statens Serum Institut
Lasse Boding is heading the Coordinating Centre at the Danish National Biobank (DNB). He holds an MSc in biochemistry and a PhD in biomedicine from the University of Copenhagen. During his Postdoc Lasse was involved in creating several research infrastructures and core facilities, which led him to the position as Coordinator at the DNB. Lasse is coordinating the research activities and responsible for securing smooth access to biological samples and corresponding data from the DNB. Other tasks involve ethical, legal and social issues (ELSI) as well as communication and outreach activities
Steve Smith, Potter Clarkson
Steve is a highly experienced European patent attorney with the firm of Potter Clarkson, based in the UK and with satellite offices in Stockholm, Lund and Munich. He specialises in biotechnology inventions, with particular expertise in therapeutic/diagnostic antibodies and disease biomarkers. He has extensive experience of patent prosecution at the European Patent Office, including oppositions and appeals, and has also supported national patent litigation in the UK and Scandinavia.
Before joining the patent profession, Steve read biochemistry at the University of Oxford and completed a doctorate degree at the same university (which included a secondment to the Karolinska Institute in Stockholm).
Steve acts for a range of clients including multinational companies, early-stage and established biotech companies based throughout Europe, as well as government-funded research institutes and universities. He is a frequent visitor to Scandinavia and represents many of the most successful biotech companies at Medicon Village and the surrounding science parks (including Alligator Bioscience, Cantargia, DiaProst, Enzymatica, Immunovia and SenzaGen).
Jonathan Robinson, Abzena
Jonathan has been working in the Pharma industry for 25 years. He started his career as a Process Engineer in a large scale Biomanufacturing plant, then moved onto to various production management roles in Small Molecule and Biologics manufacturing. He started his first commercial role in 2006 with Avecia vaccines as Director of Contracts.
Since then, he established the molecular diagnostics service provider ”NewGene” with NHS Newcastle, one of the first to support clinical stratification of patients through genotyping.
Following this he moved to the Centre for Process Innovation where he secured £38m Government funding for the National Biologics Manufacturing Centre, the UKs Biopharmaceutical industry innovation facility. As Head of Business Development he secured multiple public grants and private contracts covering the development and manufacture of the next generation of Biopharmaceuticals which continue to keep the facility busy.
At Abzena he heads business development activities for Biologics development and manufacturing integrated services in the EMEA region, from discovery, through protein engineering to process development and manufacturing.
Med.Dr Lars Lindskold, Project leader SweLife. Working in the Life Science sector for a long time. Experience of sharing data from Healthcare. Working also as senior lecture in Informatics at University of Gothenburg , and as Regional developer officer at Region Västra Götaland, Sweden. “Sharing is Caring “
Nick Lench, Congencia
Nick is Founder, COO and Executive Director of Congenica Ltd. Prior to joining Congenica full-time, Nick was the Director of the NE Thames Regional Genetics Service at Great Ormond Street Hospital for Children, London and has honorary appointments with the UCL Institute of Child Health and St. George’s University of London. Nick was also the founding Chief Executive Officer of London Genetics Ltd, a company created to facilitate collaborative research between industry and academic/NHS centres of excellence in genetics and genomics-based medicine. Previous appointments include Director of the Wales Gene Park, Cardiff University, and Discovery Genetics Programme Director, Oxagen Limited. He was awarded a personal chair in Medical Genetics at Cardiff University in 2005 and has authored over 125 peer-reviewed publications.
Dorte X. Gram
Dorte X. Gram, Pila Pharma
Dorte X. Gram (Danish, born 1969) is the Chief Executive Officer (CEO) and XENIA PHARMA’s representative in PILA PHARMA’s Board of Directors.
Dorte X. Gram is the inventor of the principle of treating diabetes and obesity with TRPV1 antagonists – a discovery-by-surprise during her PhD studies at Novo Nordisk, Denmark. In 2008, she acquired the rights to the invention from Novo Nordisk, Denmark, had use-patents issued via her mother-company XENIA PHARMA, Denmark and, in 2014, founded PILA PHARMA in Sweden as a subsidiary.
Besides her innovative and entrepreneurial drive, Dorte X. Gram provides experience to PILA PHARMA in diabetes project management and planning including preclinical and clinical pharmacology, toxicology and regulatory affairs. She further has an extensive network in diabetes and runs PILA as a virtual company with a basic focus on target product profile, lean project management and engagement of her various professional contacts and other experts.
Evy Lundgren-Åkerlund, Xintela
Founder and CEO of Xintela since with extensive experience of biomedical research and development. Have previously held leading positions in both academia and industry. Founder of Cartela AB and was CEO/CSO between 2000 and 2007. Held the position of CEO for Ideon Bioincubator/Lund Life Science Incubator 2008-2012
Lars Hedbys, Idogen
Lars Hedbys is co-founder of Idogen and partner in Ventac Partners since 2006 with over 20 years experience in senior and executive roles within the life science industry. His previous assignments include CEO roles in public and private companies and Vice President and Site General Manager roles in AstraZeneca.
Lars Hedbys is also co-founder of a number of international pharmaceutical companies. He has a long experience from board roles in a number of biotech and medtech companies and is currently Chairman of IAmPatient AB in Lund and board member of RhoVac AB (publ). Lars Hedbys holds an M.Sc. in chemical engineering from Chalmers University of Technology in Gothenburg and a Ph.D. in applied biochemistry from Lund Institute of Technology.
Abel Ureta-Vidal, Eagle Genomics
With over 20 years bioinformatics experience and a scientific background in molecular biology and immunovirology (PhD from the Pasteur Institute, France), Abel got first to grips with bioinformatics tools and code in the early 90s whilst working on viral phylogenetic studies.
After his PhD, he joined the effort at Genoscope (Evry, France) in ramping up the human genome project, putting in place the automatic gene annotation system for human chromosome 14. In 2001, he moved to the European Bioinformatics Institute (Cambridge, UK) where he led the Ensembl comparative genomics team until 2007.
He then founded Eagle Genomics shortly before graduating from the Cambridge Judge Business School MBA program in 2008.
For the last 10 years he has been one of the driving force within the executive team at Eagle, supporting the strategy and partnership activities as well as setting up a world-class company operation able to adapt to market demand. This has enabled the company to sustain its growth and extend its activities horizontally from the traditional pharma/biotech sector into sectors as diverse as plant breeding, animal health, consumer goods and food safety
Susanna Myhre, PhD
Academic Alliances Manager, Scientific Partnering and Alliances, AstraZeneca
Susanna Myhre, PhD
Susanna Myhre joined AstraZeneca in 2012 and currently holds a position as Academic Alliances Manager in the Scientific Partnering and Alliances team supporting the Cardiovascular and Metabolic Diseases (CVMD). Susanna has experience from leading major transactions mainly for academic collaborations, globaly, with responsibilities of evaluation, negotiation and execution of agreements.
Susanna began her pharma career with AstraZeneca in 2012 where she held scientific research and project leader positions for discovery projects in area of cardiovascular and metabolism diseases. Susanna holds a PhD, from Gothenburg University, performed at a biotech company in field of gene therapy and continued with a postdoctoral training at Wallenberg laboratory at Gothenburg University.
Johnson & Johnson
Johan Liwing, Johnson & Johnson
Johan is currently Global Director Market Access RWE Partnerships. In his current role Johan is coordinating efforts of developing close collaborations between Janssen and other parties in RWE research. Furthermore, Johan is leading the Janssen team in the collaboration with Karolinska Institute in advanced real world data analysis. Before joining Janssen in 2007 Johan worked as a health economist at Roche. Johan has been working with big data analysis in different areas such as finance and engineering before joining the health care sector. Over the last decade Johan has developed a research passion for how analysis of routine clinical data, especially in the field of hematology, can be used in decision making.
March 22nd, 2018
Medicon Village AB (Restaurang Inspira)
Scheelevägen 2, Lund
Please make sure that you have filled in your personal and company profile. This is necessary to enable other participants to search you and find you in the system and thus be able to make meeting requests with you. The system will be open for submitting requests until 10.00 PM. on March 21st. Only mutual availability between delegates will be scheduled.